First-in-class vaccine against IDO and PD-L1 enhances anti-PD-1 in phase I/II clinical trial
December 22, 2021
Drugs targeting the PD-1/PD-L1 axis, like nivolumab, have revolutionized treatment of patients with metastatic melanoma. However, many patients still either do not respond or develop resistance to therapy. In an effort to modulate tumor microenvironments (TMEs) to enhance responses to anti-PD-1 therapy, Kjeldsen and Lorentzen et al. tested an immune-modulatory vaccine, IO102/IO103, to induce...
B cells and CD4+ T cells are the stage crew for antitumor immunity
December 15, 2021
CD8+ T cells are often the focus of research in cancer immunotherapy, but recent evidence has suggested that CD4+ T helper cells (particularly T follicular helper [TFH] cells) and B cells (particularly germinal center [GC] B cells) may also play important behind-the-scenes roles in supporting CD8+ T cells and antitumor immune responses. Cui...
Innate immunity heats up tumors for immunotherapy response
December 8, 2021
While the precise features enabling patient response to immune checkpoint blockade (ICB) remain unclear, “hot” tumors displaying immune activity and inflammation tend to respond better than quiet, “cold” tumors. Therapies that flip this switch could extend ICB response to a broader set of patients. In Cell Reports, Wang et al. reported on a...
SITC Annual Meeting 2021
December 1, 2021
In November, the ACIR team attended the SITC Annual Meeting 2021. This week’s extensive special feature covers select talks from the conference. We have organized the content by topics below. T cell therapiesCrystal MackallDavid O’MalleyAlena GrosCassian YeeTumor microenvironment and tumor immunologyLisa M. CoussensChristine MoussionJuan R. Cubillos-RuizGiacomo OliveiraEllen PuréJorge Mansilla-SotoCheckpoint blockade and in situ...